Anti-TNF agents for rheumatoid arthritis.
暂无分享,去创建一个
H. Seymour | A. Worsley | J. Smith | S. H. Thomas | H E Seymour | A Worsley | J M Smith | S H Thomas
[1] H. Capell,et al. Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis. , 1992, Annals of the rheumatic diseases.
[2] J. Woody,et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.
[3] D. Felson,et al. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. , 1990, Arthritis and rheumatism.
[4] J. Kirwan,et al. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. , 1986, British journal of rheumatology.
[5] D. Symmons,et al. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. , 1998, British journal of rheumatology.
[6] D. Furst,et al. Etanercept Therapy in Rheumatoid Arthritis , 1999, Annals of Internal Medicine.
[7] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[8] A. Cats,et al. Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. , 1984, The Journal of rheumatology.
[9] J. Kremer,et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.
[10] Update in Rheumatology , 1999, Annals of Internal Medicine.
[11] A. Silman,et al. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? , 1999, Arthritis and rheumatism.
[12] P. Hannonen,et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial , 1999, The Lancet.
[13] D. Heijde,et al. EFFECTS OF HYDROXYCHLOROQUINE AND SULPHASALAZINE ON PROGRESSION OF JOINT DAMAGE IN RHEUMATOID ARTHRITIS , 1989, The Lancet.
[14] P. Brooks. Clinical management of rheumatoid arthritis , 1993, The Lancet.
[15] E. Yelin,et al. The economic impact of the rheumatic diseases in the United States. , 1989, The Journal of rheumatology.
[16] Epstein Wv. Treatment of rheumatoid arthritis with a tumor necrosis factor receptor-Fc fusion protein. , 1997 .
[17] D A Bloch,et al. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. , 1991, Arthritis and rheumatism.
[18] H. Paulus,et al. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. , 1990, Arthritis and rheumatism.
[19] J. Woody,et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.
[20] M. Hochberg,et al. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. , 1981, Epidemiologic reviews.
[21] A. Reiff,et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.
[22] F. Breedveld,et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[23] F. Brennan,et al. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. , 1998, Transplantation proceedings.
[24] E. Tindall,et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.
[25] P. Lipsky,et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.
[26] David T. Felson,et al. THE COMPARATIVE EFFICACY AND TOXICITY OF SECOND LINE DRUGS IN RHEUMATOID ARTHRITIS , 1990 .